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http://dx.doi.org/10.1016/j.bgm.201
2214-0247/Copyright ª 2014, TaiwanAbstract As chemotherapy causes severe and harmful drug reactions in most of the colo-
rectal cancer patients, predictive biomarkers for treatment efficacy are needed for these pa-
tients. In the present study, we investigated the prevalence of single nucleotide
polymorphisms related to genes associated with chemotherapeutic agents, 5-fluorouracil plus
oxaliplatin or irinotecan, in 255 colorectal cancer patients in southern Taiwan. EGFR codon
497G>A, GSTP1 codon 105 A>G, XPD codon 751 A>C, DPD IVS14 þ 1G>A, ERCC1 codon 118
C>T, and UTG1A1 3156 G>A were amplified by polymerase chain reaction and then sequenced.
The prevalence of genotypes EGFR codon 497 A/A, GSTP1 codon 105 G/G, XPD codon 751 C/C,
DPD IVS14 þ 1 A/A, ERCC1 codon 118 T/T, and UGT1A1 3156 AA was 33.73%, 3.01%, 0.39%, 0%,
2.88%, and 1.18%, respectively. However, the correlation between the results of 5-fluorouracil, Division of Medical Research, Fooyin University Hospital, Number 5, Jhongshan Road, Donggang
ang, Institute of Biomedical Sciences, National Sun Yat-Sen University, 70 Lienhai Road, Kaohsiung
ysu.edu.tw (L.-S. Chang), srlin@ms2.hinet.net (S.-R. Lin).
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184 C.-T. Chao et al.plus oxaliplatin or irinotecan therapy and the frequencies of these single nucleotide polymor-
phisms needs further investigation.
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Taiwan LLC. All rights reserved.Table 1 Sequences of the primer for studied
polymorphisms.
Gene Primer sequence
EGFR FW 50-TGCTGTGACCCACTCTGTCT-30
RW 50-CCAGAAGGTTGCACTTGTCC-30
GSTP1 FW 50-ACCCCAGGGCTCTATGGGAA-30
RW 50-TGAGGGCACAAGAAGCCCCT-30
XPD FW 50-TCTGCAGGAGGATCAGCTG-30
RW 50-GCAAGACTCAGGAGTCAC-30
DPD FW 50-ATCAGGACATTGTGACATATGTTTC-30
RW 50-CTTGTTTTAGATGTTAAATCACACATA-30
ERCC1 FW 50-GCAGAGCTCACCTGAGGAAC-30
RW 50-GAGGTGCAAGAAGAGGTGGA-30
UGT1A1 FW 50-ACCTCTAGTTACATAACCTGAA-30
RW 50-AATAAACCCGACCTCACCAC-30
FW Z forward primer; RW Z reverse primer.Introduction
Colorectal cancer (CRC) was newly diagnosed in 15,315
people and claimed 4921 lives in Taiwan in 2012.1 Surgical
resection has been the standard curative therapy for CRC
patients in the past few decades. However, only 1228 of the
new cases (8.02% of all the new CRC cases) in 2012 were
identified as having carcinoma in situ at the time of their
initial diagnosis.1 As a result, the majority of patients
required chemotherapy perioperatively. The mean survival
of patients with metastatic CRC after chemotherapy has
been prolonged from 14.2 months to 29.3 months2; how-
ever, chemotherapy also causes severe and potentially life-
threatening adverse drug reactions (grade 3, 4, or 5
toxicity) in almost 80% of patients.3 How to improve the
efficacy of chemotherapy and limit the attendant toxicity is
thus an issue of significant importance in the field of per-
sonal medicine.
Pharmacogenetic studies have previously sought to
investigate the associations between single nucleotide
polymorphisms (SNPs) and disease prognosis or response to
treatment in patients with CRC.4e14 Typically, these SNPs
are located within the genes of the key enzymes involved in
the pathogenesis of the disease,4,5,7,12 or in the activa-
tion,4,10,14 metabolism,14 and detoxication4,6,9,13 of specific
anticancer medicines, such as 5-fluorouracil (5-FU),4,10,14
oxaliplatin,7,12 and irinotecan.4,6,10,13 Some of them are
reported to effectively predict the response to treatment.
Glutathione S-transferase pi 1, encoded by GSTP1, cata-
lyzes the conjugation of a metabolite of oxaliplatin,
platinum-diaminocyclohexane, to glutathione. Poly-
morphism of codon 105 A>G results in the substitution of
isoleucine by valine, which lowers its enzymatic capacity
and, therefore, is reported to be associated with
oxaliplatin-related neurotoxicity.9,12 ERCC1 codon 118 T/T
exhibits a higher expression level and, therefore, better
DNA repair capacity after it is damaged by a chemothera-
peutic agent, such as oxaliplatin.7 DPD IVS14 þ 1 G>A leads
to skipping of entire exon 14, loss of enzymatic activity of
dihydropyrimidine dehydrogenase, and severe toxicity of 5-
FU.14 Uridine diphosphate-glucuronosyltransferase-A1, a
product of UGT1A1, is responsible for metabolism of an
active metabolite of irinotecan to an inactive metabolite.
The 3156 G>A variant is reported to be a good predictor of
UGT1A1 status and severity of irinotecan toxicity.13 EGFR
codon 497 G allele indicates a higher risk of local recur-
rence in advanced rectal cancer.15 However, the feasibility
of their application in the real world depends on the
prevalence of SNPs among patients with CRC. In the present
study, we report the prevalence of major SNPs in patients
with CRC who were going to receive chemotherapy at a
hospital in southern Taiwan.Materials and methods
We chose 255 patients with stage IIeIII CRC who had no
additionalmalignant disease andwere treatedwith 5-FUplus
oxaliplatin or irinotecan at Kaohsiung Medical University
Hospital, Kaohsiung, Taiwan. The Institutional Review Board
of KaohsiungMedical UniversityHospital approved this study.
We also obtained consent from all the participants and/or
their guardians for the use of their blood samples.
Based on our previous study results and references, six
SNPs (EGFR codon 497 G>A, GSTP1 Codon 105 A>G, XPD
Codon 751 A>C, DPD IVS14 þ 1G>A, ERCC1 Codon 118 C>T,
and UGT1A1 3156 G>A) were selected for analysis. DNA was
isolated with the QIAmp DNA Blood Mini Kit (Qiagen,
Alameda, CA, USA) from the blood samples. Otherwise, we
obtained appropriate primers for these genes through the
use of bioinformatics and references (Table 1),4,11e13 and
carried out polymerase chain reaction assays to obtain the
required fragments. Each polymerase chain reactionmixture
contained 80 ng of DNA, 0.2 mM of each primer (Sigma-
Aldrich, St. Louis, MO, USA), 200 mM of deoxynucleotide
triphosphate (Idaho Technologies, Salt Lake City, UT, USA),
0.625 units of Taq DNA polymerase (New England BioLabs
Inc., Ipswich, MA, USA), and 1 standard Taq reaction buffer
(New England BioLabs Inc.) in a 25-mL reaction volume.
Products of the polymerase chain reactions were then
sequenced by Mission Biotech Co., Ltd (Taipei, Taiwan).
Finally, we analyzed the frequency distribution of every SNP.
Results
From these six gene polymorphisms (EGFR codon 497 G>A,
GSTP1 codon 105 A>G, XPD codon 751 A>C, DPD
SNP of CRC patients treated with chemotherapy 185IVS14 þ 1G>A, ERCC1 codon 118 C>T, and UGT1A1 3156
G>A),wediscovered the frequencies of polymorphisms in 255
CRC patients (Table 2). According to the frequency distribu-
tions, the highest genotype of EGFR codon 497 G>A was G/A
(45.88%; nZ 177), whereas that of ERCC1 codon 118 C>Twas
C/C (55.29%; nZ 141); the lowest genotype of GSTP1 codon
105 A>G was G/G (2.75%; nZ 7), whereas that of XPD codon
751A>CwasC/C (0.39%; nZ 1) and that ofUGT1A13156G>A
was A/A (1.18%; n Z 3). In particular, for the frequency of
DPD IVS14 þ 1 G>A, the G/G genotype was the highest
(98.43%; n Z 251), whereas the A/A genotype was 0%.
Furthermore, one unexpected finding was that the frequency
of the EGFR codon 497 G/G genotype (20.39%, n Z 52) was
lower than that of the G/A genotype (45.88%, nZ 117).
Discussion
Frequency distributions ofUTG1A1 3156G/A andGSTP1 codon
105 G/G were higher than those reported by Innocenti et al8
and Kweekel et al,9 but those of XPD codon 751 C/C and
ERCC1 codon118T/Twere lower than those reportedbyRuzzo
et al.10 However, our result regarding the frequency distribu-
tion of the ERCC1 codon 118 C/C (55.29%) was comparable to
that reported by Chang et al,7 whose results suggest an asso-
ciation between ERCC1 codon 118 C>T polymorphism and the
outcome of chemotherapy in Asian patients with metastatic
CRC. According to the hypothetical model proposed by
Amstutz et al,14 a 1% difference in allele frequency between
two population groups would cause a 10% increase in the ab-
solute risk or a three-fold increase in the relative risk for
developing drug toxicity.
In conclusion, our work reported the prevalence of several
important SNPs in Taiwanese CRC patients. Impli
cations of these differences are complex, and their impacts
on prognostic and/or predictive value merit furtherTable 2 Frequency of gene polymorphisms in 255 CRC
patients.
Gene Polymorphism Genotype Patient no. (%)
(n Z 255)
EGFR Codon 497 G>A G/G 52 (20.39)
G/A 117 (45.88)
A/A 86 (33.73)
GSTP1 Codon 105 A>G A/A 175 (68.63)
A/G 73 (28.63)
G/G 7 (2.75)
XPD Codon 751 A>C A/A 184 (72.16)
A/C 70 (27.45)
C/C 1 (0.39)
DPD IVS14 þ 1G>A G/G 251 (98.43)
G/A 4 (1.57)
A/A 0 (0)
ERCC1 Codon 118 C>T C/C 141 (55.29)
T/C 99 (38.82)
T/T 15 (2.88)
UGT1A1 3156 G>A G/G 206 (80.78)
G/A 46 (18.04)
A/A 3 (1.18)
CRC Z colorectal cancer.investigations. Therefore,wewill further compare the results
of 5-FU plus oxaliplatin or irinotecan therapy with the fre-
quencies of these SNPs in 255 patients in thehopeof obtaining
information that can increase the benefits of 5-FU plus oxa-
liplatin or irinotecan chemotherapy in future clinical use.Conflicts of interest
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